| 摘要 |
PCT No. PCT/KR94/00136 Sec. 371 Date Apr. 24, 1995 Sec. 102(e) Date Apr. 24, 1995 PCT Filed Oct. 12, 1994 PCT Pub. No. WO96/11017 PCT Pub. Date Apr. 18, 1996The present invention relates to a novel use of a biologically active protein, p53 as an inhibitor of hepatitis B virus(HBV) replication. The inhibitory role of p53 on HBV replication was assessed by the reduced levels of three different markers, i.e., HBsAg and HBc/eAg secreted into the medium, HBV DNA, and RNAs. Based on the above results, it was concluded that wild-type p53 specifically represses the activity of pregenomic/core promoter of HBV and inhibits the replication of HBV by down-regulation of the pregenomic/core promoter. Therefore, the present invention provides a novel use of protein p53 as a HBV replication inhibitor which can be developed into an agent for the treatment of acute/chronic hapatitis and prevention of liver cirrhosis and hepatocellular carcinoma(HCC) caused by HBV.
|
